Strategies targeting these mechanisms, such as pharmacological inhibition of BCAT1, KDM6A/B, and glycolysis, could be effective in reversing EGFR-TKI resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.